Triple Negative Breast Neoplasms
📧 Sign up to get email alerts when something new happens for Triple Negative Breast Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-28EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
Trodelvy (sacituzumab govitecan) has been authorised by the EMA for breast cancer indications including triple-negative breast cancer.
-
EMA approval · 2026-07-16EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
EMA authorised Trodelvy (sacituzumab govitecan) for breast neoplasms, including triple negative breast neoplasms, with Gilead Sciences Irela…